SG11201809223PA - Erbb inhibitors and uses thereof - Google Patents

Erbb inhibitors and uses thereof

Info

Publication number
SG11201809223PA
SG11201809223PA SG11201809223PA SG11201809223PA SG11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA SG 11201809223P A SG11201809223P A SG 11201809223PA
Authority
SG
Singapore
Prior art keywords
international
pct
ell
english
april
Prior art date
Application number
SG11201809223PA
Inventor
Christopher Novotny
Kevan Shokat
Weijun Shen
Original Assignee
Univ California
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Scripps Research Inst filed Critical Univ California
Publication of SG11201809223PA publication Critical patent/SG11201809223PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE HO Ell 0 I MINH HO Ell I MI MI MI Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/184775 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, C07D 519/00 (2006.01) A61K 31/495 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (21) International Application Number: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, PCT/US2017/028437 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 19 April 2017 (19.04.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, TM), ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/324,864 19 April 2016 (19.04.2016) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: THE REGENTS OF THE UNIVERSITY OF KM, ML, MR, NE, SN, TD, TG). CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607 (US). Published: (72) Inventor; and — with international search report (Art. 21(3)) (71) Applicant: SHEN, Weijun [CN/US]; 13453 Sydney Rae — before the expiration of the time limit for amending the Place, San Diego, CA 92129 (US). claims and to be republished in the event of receipt of — (72) amendments (Rule 48.2(h)) Inventors: NOVOTNY, Christopher; 1071 Natoma — with sequence listing part of description (Rule 5.2(a)) Street, San Francisco, CA 94158 (US). SHOKAT, Kevan, — = M.; 783 35th Avenue, San Francisco, CA 94121 (US). Agent: TERRANOVA, Zachary, L. et al.; Mintz Levin = (74) Cohn Ferris Glovsky And Popeo, P.C., 3580 Cannel Moun- tain Road, Suite 300, San Diego, CA 92130-6768 (US). Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, _ _ = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = = Title: ERBB INHIBITORS AND USES THEREOF (54) = = = = FIG. 5B = = — SafFS Coll Panel = - 4 - 21T/3 , 10 4 1L-3 awl + MG _ : 104 g I 1-1 ir) IN Ir---- $ ll• 0 0 .7 GC Lo o lf17111). i 11 IN 11 0 ei (57) 0 : Described herein, inter alia, are compositions of ErbB modulators and methods of using the same.
SG11201809223PA 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof SG11201809223PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324864P 2016-04-19 2016-04-19
PCT/US2017/028437 WO2017184775A1 (en) 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
SG11201809223PA true SG11201809223PA (en) 2018-11-29

Family

ID=60116344

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809223PA SG11201809223PA (en) 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof

Country Status (13)

Country Link
US (1) US20190119284A1 (en)
EP (1) EP3445768A4 (en)
JP (1) JP2019514869A (en)
CN (1) CN109952306A (en)
AU (1) AU2017253096A1 (en)
BR (1) BR112018071592A8 (en)
CA (1) CA3021324A1 (en)
EA (1) EA201892368A1 (en)
IL (1) IL262400A (en)
MX (1) MX2018012797A (en)
PH (1) PH12018502233A1 (en)
SG (1) SG11201809223PA (en)
WO (1) WO2017184775A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200014298A (en) * 2017-04-28 2020-02-10 시애틀 지네틱스, 인크. Treatment of HER2-positive cancer
EP3831823A4 (en) * 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
BR112021013460A2 (en) 2019-01-11 2021-09-21 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND ANTITUMOR AGENTS WHICH COMPRISE THE SAME AND USES OF SAID COMPOUND FOR TUMOR TREATMENT
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
CN111303158A (en) * 2020-04-09 2020-06-19 成都睿智化学研究有限公司 Preparation method of (4-chloro-1H-pyrazoline [3,4-d ] pyrimidine-3-yl) aryl ketone
EP4183395A1 (en) * 2020-07-15 2023-05-24 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
ES2150113T3 (en) * 1995-04-03 2000-11-16 Novartis Ag DERIVATIVES OF PIRAZOLE AND PROCEDURES FOR THE PREPARATION OF THE SAME.
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
CN101124228B (en) * 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 Pyrazolopyrimidine compounds as antitumor agents
AU2008240188A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
WO2011013656A1 (en) * 2009-07-28 2011-02-03 第一三共株式会社 Pyrrolo[2,3-d]pyrimidine derivative
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN103570723B (en) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 Pyrazolopyrimidine derivative and preparation method thereof and the purposes in prepared by medicine

Also Published As

Publication number Publication date
IL262400A (en) 2018-12-31
BR112018071592A2 (en) 2019-02-12
JP2019514869A (en) 2019-06-06
EA201892368A1 (en) 2019-05-31
CN109952306A (en) 2019-06-28
BR112018071592A8 (en) 2019-02-26
CA3021324A1 (en) 2017-10-26
PH12018502233A1 (en) 2019-06-03
US20190119284A1 (en) 2019-04-25
MX2018012797A (en) 2020-01-09
AU2017253096A1 (en) 2018-11-08
WO2017184775A1 (en) 2017-10-26
EP3445768A1 (en) 2019-02-27
EP3445768A4 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
SG11201809223PA (en) Erbb inhibitors and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201811074RA (en) Nant cancer vaccine
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201907023UA (en) Method of reducing neutropenia
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof